Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins

Biotechnology Journal

Volumn 7, Issue 12, 2012, Pages 1473-1484

  Van Beers, Miranda M C ^a   Bardor, Muriel ^a  

^a AGENCY FOR SCIENCE   (Singapore)

Author keywords

Immune response; Mammalian biotechnology; Pharmaceuticals; Post translational modification; Protein structure

Indexed keywords

BIOPHARMACEUTICAL PRODUCTS; BIOPHARMACEUTICALS; CLINICAL TRIAL; CRITICAL QUALITY; DOWNSTREAM-PROCESSING; DRUG DESIGN; HUMAN HOMOLOGUE; IMMUNE RESPONSE; IMMUNE SYSTEMS; IMMUNOGENICITY; POST-TRANSLATIONAL MODIFICATIONS; PRODUCT QUALITY; PROTEIN CONFORMATION; PROTEIN STRUCTURES; STRUCTURAL CHARACTERISTICS; THERAPEUTIC PROTEIN;

CHEMICAL MODIFICATION; DRUG PRODUCTS; IMMUNOLOGY; MAMMALS; PRODUCT DESIGN; QUALITY CONTROL;

PROTEINS;

ALPHA INTERFERON; BIOLOGICAL PRODUCT; GLYCAN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PROTEIN;

B LYMPHOCYTE; CELL LINE; CHEMICAL MODIFICATION; CLINICAL TRIAL (TOPIC); DEGRADATION; DRUG DESIGN; DRUG MANUFACTURE; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN STRUCTURE; QUALITY CONTROL; REVIEW; T LYMPHOCYTE;

ANIMALS; BIOPHARMACEUTICS; BIOTECHNOLOGY; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT PROTEINS;

MAMMALIA;

EID: 84870704743     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201200065     Document Type: Review

References (96)

1. Walsh, G., Biopharmaceutical benchmarks 2010. Nat. Biotech. 2010, 28, 917-924.
2. Goodman, M., Market watch: sales of biologics to show robust growth through to 2013. Nat. Rev. Drug Discov. 2009, 8, 837-837.
3. Schellekens, H., Biosimilar therapeutics - what do we need to consider? NDT Plus 2009, 2, i27-i36.
4. Schellekens, H., Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 2002, 1, 457-462.
5. Casadevall, N., Nataf, J., Viron, B., Kolta, A. et al., Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002, 346, 469-475.
6. Schernthaner, G., Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 1993, 16, 155-165.
7. Heding, L. G., Larsson, Y., Ludvigsson, J., The immunogenicity of insulin preparation. Antibody levels before and after transfer to highly purified porcine insulin. Diabetologia 1980, 19, 511-515.
8. Moore, W. V., Leppert, P., Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrinol. Metab. 1980, 51, 691-697.
9. Baker, M., Reynolds, H. M., Lumicisi, B., Bryson, C. J., Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 2010, 1, 314-322.
10. Ordas, I., Mould, D. R., Feagan, B. G., Sandborn, W. J., Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin. Pharmacol. Ther. 2012, 91, 635-646.
11. Jiskoot, W., Randolph, T. W., Volkin, D. B., Middaugh, C. R. et al., Protein instability and immunogenicity: roadblocks to clinical application of injectable protein delivery systems for sustained release. J. Pharm. Sci. 2012, 101, 946-954.
12. Hermeling, S., Crommelin, D., Schellekens, H., Jiskoot, W., Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 2004, 21, 897-903.
13. Singh, S. K., Impact of product-related factors on immunogenicity of biotherapeutics. J. Pharm. Sci. 2011, 100, 354-387.
14. Eon-Duval, A., Broly, H., Gleixner, R., Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol. Prog. 2012, 28, 608-622.
15. Rathore, A. S., Winkle, H., Quality by design for biopharmaceuticals. Nat. Biotechnol. 2009, 27, 26-34.
16. Marini, J. C., Chapter 8: Cell cooperation in the antibody response, in: Male, D., Brostoff, J., Roth, D. B., Roitt, I. (Eds.), Immunology, Elsevier Limited, Philadelphia 2006, pp. 163-180.
17. Abbas, A. K., Lichtman, A. H., Chapter 9: Immunologic tolerance and autoimmunity, in: Malley, J. (Ed.), Basic Immunology: Functions and Disorders of the Immune System, Elsevier Saunders, Philadelphia 2006, pp. 161-176.
18. Rosenberg, A. S., Effects of protein aggregates: an immunologic perspective. AAPS J. 2006, 8, E501-E507.
19. Bachmann, M. F., Zinkernagel, R. M., Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 1997, 15, 235-270.
20. Sauerborn, M., Brinks, V., Jiskoot, W., Schellekens, H., Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol. Sci. 2010, 31, 53-59.
21. Defrance, T., Taillardet, M., Genestier, L., T cell-independent B cell memory. Curr. Opin. Immunol. 2011, 23, 330-336.
22. Schellekens, H., Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 2002, 24, 1720-1740.
23. Jefferis, R., Human immunoglobulin allotypes: possible implications for immunogenicity. mAbs 2009, 1, 332-338.
24. Harding, F. A., Stickler, M. M., Razo, J., DuBridge, R. B., The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010, 2, 256-265.
25. Rispens, T., de Vrieze, H., de Groot, E., Wouters, D. et al., Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J. Immunol. Methods 2012, 375, 93-99.
26. de Laat, B., van Berkel, M., Urbanus, R. T., Siregar, B. et al., Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: domain I of β2-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum. 2011, 63, 3960-3968.
27. Maas, C., Hermeling, S., Bouma, B., Jiskoot, W., Gebbink, M. F. B. G., A role for protein misfolding in immunogenicity of biopharmaceuticals. J. Biol. Chem. 2007, 282, 2229-2236.
28. De Groot, A. S., Scott, D. W., Immunogenicity of protein therapeutics. Trends in Immunology 2007, 28, 482-490.
29. Kumar, S., Singh, S., Wang, X., Rup, B., Gill, D., Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions. Pharm. Res. 2011, 28, 949-961.
30. Brooks, S. A., Chapter 4: Species differences in protein glycosylation and their implications for biotechnology, in: Brooks, S., Rudd, P., Appelmelk, B. (Eds.), Glycosylation in Diverse Cell Systems: Challenges and New Frontiers in Experimental Biology, Society for Experimental Biology, London 2011, pp. 74-92.
31. Ezzelarab, M., Ayares, D., Cooper, D. K. C., Carbohydrates in xenotransplantation. Immunol. Cell. Biol. 2005, 83, 396-404.
32. Galili, U., The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol. Cell. Biol. 2005, 83, 674-686.
33. Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T. et al., Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1, 3-galactose. N. Engl. J. Med. 2008, 358, 1109-1117.
34. Chung, C. H., Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 2008, 13, 725-732.
35. Qian, J., Liu, T., Yang, L., Daus, A. et al., Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal. Biochem. 2007, 364, 8-18.
36. Maeda, E., Kita, S., Kinoshita, M., Urakami, K. et al., Analysis of nonhuman N-glycans as the minor constituents in recombinant monoclonal antibody pharmaceuticals. Anal. Chem. 2012, 84, 2373-2379.
37. Saleh, H., Embry, S., Nauli, A., Atyia, S., Krishnaswamy, G., Anaphylactic reactions to oligosaccharides in red meat: a syndrome in evolution. Clin. Mol. Allergy 2012, 10, 5.
38. Jefferis, R., Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol. Sci. 2009, 30, 356-362.
39. Bosques, C. J., Collins, B. E., Meador, J. W., Sarvaiya, H. et al., Chinese hamster ovary cells can produce galactose-α-1, 3-galactose antigens on proteins. Nat. Biotech. 2010, 28, 1153-1156.
40. Padler-Karavani, V., Varki, A., Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk. Xenotransplantation 2011, 18, 1-5.
41. Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., Varki, A., Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat. Biotechnol. 2010, 28, 863-867.
42. Bardor, M., Nguyen, D. H., Diaz, S., Varki, A., Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J. Biol. Chem. 2005, 280, 4228-4237.
43. Aviezer, D., Brill-Almon, E., Shaaltiel, Y., Hashmueli, S. et al., A plant-derived recombinant human glucocerebrosidase enzyme - A preclinical and phase I investigation. PLoS One 2009, 4, e4792.
44. Hiatt, A., Caffferkey, R., Bowdish, K., Production of antibodies in transgenic plants. Nature 1989, 342, 76-78.
45. Bardor, M., Loutelier-Bourhis, C., Paccalet, T., Cosette, P. et al., Monoclonal C5-1 antibody produced in transgenic alfalfa plants exhibits a N-glycosylation that is homogenous and suitable for glyco-engineering into human-compatible structures. Plant Biotechnol. J. 2003, 1, 451-462.
46. Bardor, M., Burel, C., Villajero, A., Cadoret, J. P. et al., Chapter 5: Plant N-glycosylation: an engineered pathway for the production of therapeutical plant-derived glycoproteins, in: Brooks, S., Rudd, P., Appelmelk, B. (Eds.), Glycosylation in Diverse Cell Systems: Challenges and New Frontiers in Experimental Biology, Society for Experimental Biology, London 2011, pp. 93-118.
47. Bardor, M., Faveeuw, C., Fitchette, A.-C., Gilbert, D. et al., Immunoreactivity in mammals of two typical plant glyco-epitopes, core α(1, 3)-fucose and core xylose. Glycobiology 2003, 13, 427-434.
48. Manduzio, H., Fitchette, A.-C., Hrabina, M., Chabre, H. et al., Glycoproteins are species-specific markers and major IgE reactants in grass pollens. Plant Biotechnol. J. 2012, 10, 184-194.
49. Runkel, L., Meier, W., Pepinsky, R. B., Karpusas, M. et al., Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm. Res. 1998, 15, 641-649.
50. van Beers, M. M. C., Jiskoot, W., Schellekens, H., On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J. Interferon Cytokine Res. 2010, 30, 767-775.
51. Gribben, J. G., Devereux, S., Thomas, N. S. B., Keim, M. et al., Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 1990, 335, 434-437.
52. Tatsumi, Y., Sasahara, Y., Kohyama, N., Ayano, S. et al., Introducing site-specific glycosylation using protein engineering techniques reduces the immunogenicity of β-lactoglobulin. Biosci. Biotechnol. Biochem. 2012, 76, 478-485.
53. Walsh, G., Jefferis, R., Post-translational modifications in the context of therapeutic proteins. Nat. Biotechnol. 2006, 24, 1241-1252.
54. Basu, A., Yang, K., Wang, M., Liu, S. et al., Structure-function engineering of interferon-β-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug. Chem. 2006, 17, 618-630.
55. Baker, D. P., Lin, E. Y., Lin, K., Pellegrini, M. et al., N-terminally PEGylated human interferon-β-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug. Chem. 2006, 17, 179-188.
56. Manning, M., Chou, D., Murphy, B., Payne, R., Katayama, D., Stability of protein pharmaceuticals: an update. Pharm. Res. 2010, 27, 544-575.
57. Torosantucci, R., Mozziconacci, O., Sharov, V., Schöneich, C., Jiskoot, W., Chemical modifications in aggregates of recombinant human insulin induced by metal-catalyzed oxidation: covalent cross-linking via Michael addition to tyrosine oxidation products. Pharm. Res. 2012, 29, 2276-2293.
58. Cleland, J., Powell, M., Shire, S., The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 1993, 10, 307-377.
59. Chen, W., Ede, N. J., Jackson, D. C., McCluskey, J., Purcell, A. W., CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. J. Immunol. 1996, 157, 1000-1005.
60. Doyle, H. A., Zhou, J., Wolff, M. J., Harvey, B. P. et al., Isoaspartyl post-translational modification triggers anti-tumor T and B lymphocyte immunity. J. Biol. Chem. 2006, 281, 32676-32683.
61. Rasheed, Z., Ali, R., Reactive oxygen species damaged human serum albumin in patients with type 1 diabetes mellitus: biochemical and immunological studies. Life Sci. 2006, 79, 2320-2328.
62. Filipe, V. L. S., Chapter 9: Immunogenicity of different stressed monoclonal IgG formulations in immune tolerant transgenic mice, in: Monoclonal antibody aggregates: physicochemical characteristics, stability in biological fluids and immunogenicity, PhD thesis, Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands 2012, pp.171-200.
63. Hermeling, S., Aranha, L., Damen, J. M. A., Slijper, M. et al., Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm. Res. 2005, 22, 1997-2006.
64. van Beers, M. M. C., Sauerborn, M., Gilli, F., Brinks, V. et al., Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm. Res. 2011, 28, 2393-2402.
65. Zhou, S., Schöneich, C., Singh, S., Biologics formulation factors affecting metal leachables from stainless steel. AAPS PharmSciTech. 2011, 12, 411-421.
66. Cromwell, M. E. M., Hilario, E., Jacobson, F., Protein aggregation and bioprocessing. AAPS J. 2006, 8, E572-E579.
67. Dresser, D. W., Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. Immunology 1962, 5, 378-388.
68. Weksler, M. E., Bull, G., Schwartz, G. H., Stenzel, K. H., Rubin, A. L., Immunologic responses of graft recipients to antilymphocyte globulin: effect of prior treatment with aggregate-free gamma globulin. J. Clin. Invest. 1970, 49, 1589-1595.
69. Seidl, A., Hainzl, O., Richter, M., Fischer, R. et al., Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm. Res. 2012, 1-14.
70. Brinks, V., Jiskoot, W., Schellekens, H., Immunogenicity of therapeutic proteins: the use of animal models. Pharm. Res. 2011, 28, 2379-2385.
71. Fradkin, A. H., Carpenter, J. F., Randolph, T. W., Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J. Pharm. Sci. 2009, 98, 3247-3264.
72. Braun, A., Kwee, L., Labow, M. A., Alsenz, J., Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm. Res. 1997, 14, 1472-1478.
73. Hermeling, S., Schellekens, H., Maas, C., Gebbink, M. F. B. G. et al., Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J. Pharm. Sci. 2006, 95, 1084-1096.
74. Pisal, D. S., Kosloski, M. P., Middaugh, C. R., Bankert, R. B., Balu-iyer, S. V., Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. J. Pharm. Sci. 2012, 101, 2055-2065.
75. Vos, Q., Lees, A., Wu, Z. Q., Snapper, C. M., Mond, J. J., B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol. Rev. 2000, 176, 154-170.
76. Dintzis, H. M., Dintzis, R. Z., Vogelstein, B., Molecular determinants of immunogenicity: the immunon model of immune response. Proc. Natl. Acad. Sci. USA 1976, 73, 3671-3675.
77. Chackerian, B., Lenz, P., Lowy, D. R., Schiller, J. T., Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol. 2002, 169, 6120-6126.
78. Jegerlehner, A., Tissot, A., Lechner, F., Sebbel, P. et al., A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002, 20, 3104-3112.
79. Wang, W., Singh, S. K., Li, N., Toler, M. R. et al., Immunogenicity of protein aggregates - Concerns and realities. Int. J. Pharm. 2012, 431, 1-11.
80. Narhi, L. O., Schmit, J., Bechtold-Peters, K., Sharma, D., Classification of protein aggregates. J. Pharm. Sci. 2012, 101, 493-498.
81. Carpenter, J. F., Randolph, T. W., Jiskoot, W., Crommelin, D. J. A. et al., Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J. Pharm. Sci. 2009, 98, 1201-1205.
82. Singh, S. K., Afonina, N., Awwad, M., Bechtold-Peters, K. et al., An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J. Pharm. Sci. 2010, 99, 3302-3321.
83. den Engelsman, J., Garidel, P., Smulders, R., Koll, H. et al., Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm. Res. 2011, 28, 920-933.
84. Zölls, S., Tantipolphan, R., Wiggenhorn, M., Winter, G. et al., Particles in therapeutic protein formulations, Part 1: overview of analytical methods. J. Pharm. Sci. 2012, 101, 914-935.
85. Bee, J. S., Davis, M., Freund, E., Carpenter, J. F., Randolph, T. W., Aggregation of a monoclonal antibody induced by adsorption to stainless steel. Biotechnol. Bioeng. 2010, 105, 121-129.
86. Fradkin, A. H., Carpenter, J. F., Randolph, T. W., Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins. J. Pharm. Sci. 2011, 100, 4953-4964.
87. van Beers, M. M. C., Gilli, F., Schellekens, H., Randolph, T. W., Jiskoot, W., Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. J. Pharm. Sci. 2012, 101, 187-199.
88. Luo, Q., Joubert, M. K., Stevenson, R., Ketchem, R. R. et al., Chemical modifications in therapeutic protein aggregates generated under different stress conditions. J. Biol. Chem. 2011, 286, 25134-25144.
89. Castillo, V., Graña-Montes, R., Sabate, R., Ventura, S., Prediction of the aggregation propensity of proteins from the primary sequence: aggregation properties of proteomes. Biotechnol. J. 2011, 6, 674-685.
90. Fernandez-Escamilla, A.-M., Rousseau, F., Schymkowitz, J., Serrano, L., Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat. Biotechnol. 2004, 22, 1302-1306.
91. Lee, C. J., Seth, G., Tsukuda, J., Hamilton, R. W., A clone screening method using mRNA levels to determine specific productivity and product quality for monoclonal antibodies. Biotechnol. Bioeng. 2009, 102, 1107-1118.
92. Rifkin, R., Maggio, E., Dike, S., Kerr, D., Levy, M., n-Dodecyl-β-D-maltoside inhibits aggregation of human interferon-β-1b and reduces its immunogenicity. J. Neuroimmune Pharmacol. 2011, 6, 158-162.
93. Buettel, I. C., Chamberlain, P., Chowers, Y., Ehmann, F. et al., Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 2011, 39, 100-109.
94. Bozhinov, A., Handzhiyski, Y., Genov, K., Daskalovska, V. et al., Advanced glycation end products contribute to the immunogenicity of IFN-β pharmaceuticals. J. Allergy Clin. Immunol. 2012, 129, 855-858.
95. van Beers, M. M. C., Sauerborn, M., Gilli, F., Brinks, V. et al., Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm. Res. 2010, 27, 1812-1824.
96. Seefeldt, M. B., Rosendahl, M. S., Cleland, J. L., Hesterberg, L. K., Application of high hydrostatic pressure to dissociate aggregates and refold proteins. Curr. Pharm. Biotechnol. 2009, 10, 447-455.